Arrowhead Pharmaceuticals, Inc. vs BioCryst Pharmaceuticals, Inc.: A Gross Profit Performance Breakdown

Biotech Giants' Gross Profit Battle: 2014-2023

__timestampArrowhead Pharmaceuticals, Inc.BioCryst Pharmaceuticals, Inc.
Wednesday, January 1, 201417500013486000
Thursday, January 1, 201538200046361000
Friday, January 1, 201615833323654000
Sunday, January 1, 20173140770923484000
Monday, January 1, 20181614232120182000
Tuesday, January 1, 201916879557744734000
Wednesday, January 1, 20208799206616136000
Friday, January 1, 2021138287000149906000
Saturday, January 1, 2022232810000264233000
Sunday, January 1, 2023240735000326751000
Monday, January 1, 20243551000
Loading chart...

Unlocking the unknown

A Tale of Two Biotechs: Gross Profit Trends from 2014 to 2023

In the competitive world of biotechnology, Arrowhead Pharmaceuticals, Inc. and BioCryst Pharmaceuticals, Inc. have shown intriguing gross profit trajectories over the past decade. Starting in 2014, BioCryst outperformed Arrowhead with a gross profit nearly 77 times higher. However, by 2019, Arrowhead surged ahead, achieving a gross profit over three times that of BioCryst. This trend continued until 2023, when BioCryst reclaimed the lead with a 36% higher gross profit than Arrowhead. Notably, 2024 data for BioCryst is missing, leaving room for speculation on future performance. These fluctuations highlight the dynamic nature of the biotech industry, where innovation and market conditions can rapidly alter financial standings. Investors and industry watchers should keep a close eye on these companies as they navigate the ever-evolving landscape of pharmaceutical development.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025